Advertisement
Advertisement
U.S. markets open in 8 hours 18 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Awakn Life Sciences Corp. (AWKNF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4723-0.0266 (-5.33%)
At close: 11:57AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4989
Open0.4989
BidN/A x N/A
AskN/A x N/A
Day's Range0.4685 - 0.4989
52 Week Range0.3500 - 2.7100
Volume7,704
Avg. Volume6,530
Market Cap12.714M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.5580
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.98
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for AWKNF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AWAKN LIFE SCIENCES CORP
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    11 hours agoMorningstar
View more
  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector Cannabis REIT IIPR generated record revenue of $70.5 million in the second quarter. Green Thumb Q2 revenue increased 5%, to $254 million. Scotts Miracle-Gro share price soared, despite the company missing earnings estimates. Key Takeaways; Psychedelic Sector Awakn received CA$2.5 government funding for phase III trial. July was a great month […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.

  • Newsfile

    Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs

    Phase III Trial to Cost approximately CA$3.75 million with Awakn's contribution expected to be approximately CA$1.25 million, Marks First Psychedelic Phase III Trial Ever to Receive Government Funding Toronto, Ontario--(Newsfile Corp. - July 20, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD

  • Newsfile

    Awakn Life Sciences Provides a Business and Corporate Update

    Toronto, Ontario--(Newsfile Corp. - July 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) is today providing a business and corporate update. Awakn launches 'Beta' phase of its Licensing and Partnerships business in North America. Awakn has signed Memorandum of Understanding (MOU) documen

Advertisement
Advertisement